<DOC>
	<DOCNO>NCT00962507</DOCNO>
	<brief_summary>RATIONALE : Panobinostat everolimus may stop growth cancer cell block enzymes need cell growth block blood flow cancer . Giving panobinostat together everolimus may kill cancer cell . PURPOSE : This phase I trial study side effect best dose panobinostat give together everolimus treat patient relapsed refractory lymphoma multiple myeloma .</brief_summary>
	<brief_title>Panobinostat Everolimus Treating Patients With Relapsed Refractory Lymphoma Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate safety feasibility combine panobinostat everolimus patient recurrent refractory lymphoma multiple myeloma . - To define maximum tolerate dose panobinostat combination everolimus patient . Secondary - To obtain preliminary data response treatment regimen patient . - To perform correlative study relevant treatment regimen . OUTLINE : This dose-escalation study panobinostat . Patients receive oral panobinostat 3 day week oral everolimus every day 4 week Courses repeat every 4 week absence disease progression unacceptable toxicity . Blood bone marrow sample may collect pharmacokinetic correlative laboratory study . After completion study treatment , patient follow ≥ 4 week .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis one following : Hodgkin nonHodgkin lymphoma ( include small lymphocytic lymphoma [ SLL ] ) Any histology , include B , T , NK/T cell allow Multiple myeloma ( MM ) Relapsed refractory disease Patients lymphoma must relapse refractory upfront regimen ( e.g. , CHOP ABVD ) salvage regimen ( e.g. , ICE ESHAP ) Patients SLL relapse fludarabinecontaining regimen Patients MM must progress within 100 day receive regimen contain bortezomib either thalidomide lenalidomide AND 25 % increase serum paraproteins , urinary light chain , plasma cell number bone marrow No active CNS disease PATIENT CHARACTERISTICS : ECOG performance status 02 ANC ≥ 1,500/mm³ Platelet count ≥ 75,000/mm³ ( transfusion allow patient biopsyproven bone marrow involvement ) AST ALT ≤ 2.5 time upper limit normal ( ULN ) ( ≤ 5.0 time ULN elevation due leukemic involvement ) Serum bilirubin ≤ 1.5 time ULN Serum creatinine ≤ 1.5 time ULN OR creatinine clearance ≥ 50 mL/min Serum potassium normal Serum phosphorous normal Serum total calcium ( correct serum albumin ) serum ionized calcium normal Serum magnesium normal TSH free T4 normal ( thyroid hormone replacement allow ) Fasting serum cholesterol ≤ 300 mg/dL ( ≤ 7.75 mmol/L ) AND fast triglyceride ≤ 2.5 time ULN ( elevate level allow provided appropriate lipidlowering medication initiate ) LVEF normal MUGA ECHO Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod ( include barrier method ) contraception 3 month completion study treatment No impaired cardiac function , include follow : QTc &gt; 450 msec screen ECG Congenital long QT syndrome History sustain ventricular tachycardia History ventricular fibrillation torsades de pointes Bradycardia , define heart rate ( HR ) &lt; 50 beats/min ( pacemaker allow provide HR ≥ 50 beats/min ) Myocardial infarction unstable angina within past 6 month NYHA class IIIIV congestive heart failure Right bundle branch block leave anterior hemiblock ( bifascicular block ) No uncontrolled hypertension No unresolved diarrhea &gt; CTCAE grade 1 No impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral agent ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , small bowel resection ) No concurrent severe uncontrolled medical condition No primary malignancy within past 5 year curatively treat carcinoma situ cervix basal cell squamous cell carcinoma skin No known HIV hepatitis C positivity No significant history noncompliance medical regimens No known hypersensitivity everolimus , rapamycins ( e.g. , sirolimus temsirolimus ) , excipients PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior autologous allogeneic stem cell transplantation allow More 3 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy recover More 1 week since prior concurrent immunization live attenuate vaccine More 4 week since prior valproic acid No prior histone deacetylase inhibitor No concurrent chronic systemic corticosteroid another immunosuppressive agent , control itching ( cutaneous Tcell lymphoma ) Concurrent corticosteroid allow provided patient stable dosage regimen ≥ 2 week study entry Topical inhale corticosteroid allow No concurrent drug may induce torsades de point No concurrent CYP3A4 inhibitors No concurrent radiotherapy anticancer therapy No concurrent grapefruit , grapefruit juice , seville ( sour ) oranges No concurrent medication may cause QTc prolongation No concurrent investigational therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>refractory multiple myeloma</keyword>
</DOC>